All In Biotech

Drug Trial Radar · NCT06206421

A Study to Assess Long-term Safety of Fezolinetant Given to Japanese Women Going Through Menopause

A Phase 3, Randomized, Placebo-controlled, Double-blind Study to Investigate the Long Term Safety of Fezolinetant in Japanese Women Suffering From Vasomotor Symptoms (Hot Flashes) Associated With Menopause

Last checked: Nov 20, 2026Latest source record: Apr 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 277 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

277

Actual

Start

Feb 22, 2024

Primary completion

Mar 19, 2026

Study completion Mar 19, 2026

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jan 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 40 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Hot flashes are the most common reason women going through menopause seek medical attention. Hormone replacement therapy, or HRT, is most often prescribed to treat hot flashes. However, HRT can't be used by all women or for as long as may be needed. Researchers want to find other ways to treat hot flashes. Fezolinetant is a medicine to treat hot flashes in women going through menopause. Fezolinetant is an approved medicine in the US. Further studies are needed before it is available in other regions such as Asia. In this study fezolinetant will be used to treat hot flashes in Japanese women going through menopause. This study will confirm the safety of fezolinetant and how well the women tolerate the treatment. Women will either take fezolinetant or a placebo. This is decided by chance alone. The placebo looks like fezolinetant but will not have any medicine in it. The women will take 1 tablet of the study medicine (fezolinetant or the placebo) once a day for up to 52 weeks. During the study, the women will visit their study clinic for a check-up about every 4 weeks for up to 52 weeks (1 year). At each visit they will be asked if they had any medical problems. Other checks will include a medical examination and vital signs (temperature, blood pressure and pulse). At some visits, the women will have an ECG to check their heart rhythm and some blood and urine samples will be taken for laboratory tests. During a couple of visits, women who have a womb (uterus) will also have a test called a transvaginal ultrasound. A probe is gently placed inside the vagina. Sound waves will create a picture of the organs in the pelvis. This will allow the study doctor to look more closely at the uterus and surrounding organs. The last clinic visit will be 3 weeks after the women take their final tablet of the study medicine (fezolinetant or the placebo).

Conditions

  • Hot Flashes

Interventions

  • FezolinetantDrug

    oral

  • PlaceboDrug

    oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with Adverse Events (AEs)Time frame: Up to Week 55

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Daido Clinic

    Nagoya, Aichi-ken, Japan

  • Juno Vesta Clinic hatta

    Matsudo-shi, Chiba, Japan

  • Mori Ladies Clinic

    Fukuoka, Fukuoka, Japan

  • Kotoni Ladies Clinic

    Sapporo, Hokkaido, Japan

  • M's Ladies Clinic

    Sapporo, Hokkaido, Japan

  • NISHIKAWA Women's Health Clinic

    Sapporo, Hokkaido, Japan

  • Motomachi Ladies Clinic

    Yokohama, Kanagawa, Japan

  • Women's Clinic LUNA Yokohama Motomachi

    Yokohama, Kanagawa, Japan

  • Chieko Yukika Lady's Clinic

    Sendai, Miyagi, Japan

  • GyNet Medical Corporation Minamimorimachi Ladies' Clinic

    Osaka, Osaka, Japan

  • Ninomiya Ladies Clinic

    Osaka, Osaka, Japan

  • Rikako Ladies Clinic

    Osaka, Osaka, Japan

  • Tennoji Chihiro Women's Clinic

    Osaka, Osaka, Japan

  • Shimizu Ladies Clinic

    Sakai-shi, Osaka, Japan

  • jMOG Medical Corporation Tanabe Ladies' Clinic

    Takatsuki-shi, Osaka, Japan

  • Marunouchi no Mori Ladies Clinic

    Chiyoda-ku, Tokyo, Japan

  • Ginza Yoshida Medical Clinic

    Chuo-ku, Tokyo, Japan

  • Medical Corporation Asbo Tokyo Asbo Clinic

    Chuo-ku, Tokyo, Japan

  • Medical Corp.SEIKOUKAI New Medical Research System Clinic

    Hachioji-shi, Tokyo, Japan

  • Kichijyoji Ladies Clinic

    Musashino-shi, Tokyo, Japan

  • Shimamura Memorial Hospital

    Nerima-ku, Tokyo, Japan

  • Yukawa Women'S Clinic

    Nishi-Tokyo-shi, Tokyo, Japan

  • Shimodaira Ladies Clinic

    Suginami-ku, Tokyo, Japan

  • Medical Corporation Associa Tamacenter Ladies Clinic

    Tama-Shi, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.